MannKind Corporation MNKD
MannKind Corporation (Nasdaq: MNKD) is a respiratory drug developer. Its lead program, MNKD-201, is in Phase 2 for idiopathic pulmonary fibrosis (IPF).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MNKD-201 | idiopathic pulmonary fibrosis (IPF) | small molecule | Phase 2 |
| MNKD-1501 (ralinepag DPI) | pulmonary arterial hypertension (in development by United Therapeutics) | small molecule | Pre-clinical |
| MNKD-701 | fluid overload (loop diuretic program) | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive MannKind reported positive Phase 1b INFLO-1 results for nintedanib DPI demonstrating tolerability in IPF patients.
Positive Phase 1b INFLO-1 results demonstrated tolerability of nintedanib DPI, validating the Technosphere® DPI platform in IPF
Filing - Nov 5, 2026started MannKind initiated a global Phase 2 trial for nintedanib DPI following positive Phase 1b results.
Advancing MNKD-201 into global Phase 2 trial
Filing - Aug 5, 2026positive Topline Phase 1b INFLO-1 data showed nintedanib DPI was safe and well tolerated in IPF patients, supporting Phase 2 advancement; no efficacy numbers given.
Topline data readout of U.S. Phase 1b INFLO-1 demonstrates safety and tolerability in IPF patients
Filing
7 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.